Sangamo's SB-FIX gene therapy granted FDA orphan drug designation for hemophilia B Sep. 8, 2016 No Comments
Bristol-Myers Squibb presents novel PAR-4 antagonists as promising antithrombotic agents Sep. 6, 2016 No Comments
Fostamatinib meets primary endpoint in the first study from the FIT phase III clinical program Aug. 31, 2016 No Comments
RSS